Phase I Clinical Study Using an Antifibrotic Drug
使用抗纤维化药物的 I 期临床研究
基本信息
- 批准号:7801522
- 负责人:
- 金额:$ 31.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-05-01 至 2011-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcuteAffectAlcohol consumptionAntiviral AgentsApplications GrantsBiological AssayBusinessesCellsCessation of lifeChronicCicatrixCirrhosisClinicClinicalClinical ResearchClinical TrialsConsultDataDevelopmentDialysis patientsDiseaseDoctor of MedicineDoctor of PhilosophyDoseDouble-Blind MethodDrug FormulationsDrug KineticsEnrollmentEpidemicExtrahepaticFibrosisFundingGenesGrantGrowth FactorHalf-LifeHepaticHepatitisHepatitis CHepatocyte Growth FactorHumanImmuneIncidenceInflammatory ResponseInjuryIntravenousIron OverloadKnowledgeLeadershipLiverLiver CirrhosisLiver FailureLiver FibrosisLiver diseasesMedical centerObstructionOralOral AdministrationPatientsPersonnel StaffingPharmaceutical PreparationsPharmacistsPhasePhase I Clinical TrialsPlacebo ControlPlacebosPopulation StudyPositioning AttributeProgram DevelopmentProteinsRandomizedRenal dialysisResearchResearch DesignResearch Project GrantsSafetySerumSolutionsSpecific qualifier valueTestingTissuesToxicologyTranslational ResearchUnited States National Institutes of HealthVirus Diseasescohortcostdesignexperiencehealthy volunteerinnovationliver transplantationmeetingsmimeticsnonalcoholic steatohepatitisnovelphase 1 studypre-clinicalprogramspublic health relevanceregenerativeresponsesmall molecule
项目摘要
DESCRIPTION (provided by applicant): Liver fibrosis, a disease affecting tens of millions of people worldwide, is the liver scarring response to chronic injury from excessive alcohol use, virus infection (hepatitis B and C), iron overload or extrahepatic obstructions and can progress to liver cirrhosis, liver failure and death. In fact, deaths from complications of liver fibrosis/cirrhosis are expected to triple over the next decade as a result of the hepatitis C epidemic and the growing incidence of liver disease associated with non-alcoholic steatohepatitis. Currently available therapies, including antivirals, are largely ineffective in treating the underlying fibrosis, and in the majority of cases, liver transplantation is the only effective cure. Hepatic growth factor (HGF), also known as scatter factor (SF), has been shown to be efficacious in reducing liver fibrosis. The feasibility of HGF as gene or protein therapy however is limited by issues relating to immune and inflammatory responses evoked by adenoviral proteins, inherent instability of proteins in solution, their limited tissue half-life, and the exorbitant costs associated with such therapy. Supported by the National Institutes of Health (NIH) Small Business Innovative Research (SBIR) and Rapid Access to Interventional Development (RAID) programs, we have identified and developed BB3, a novel small molecule HGF mimetic. BB3 duplicates the bioactivities of HGF in every assay tested to date. Particularly, BB3 possesses cell protective, anti-fibrotic, and regenerative activities and shows efficacy in reducing liver fibrosis. The overall objective of our program is to advance BB3 to the clinic as a first-in-class antifibrotic for liver fibrosis. From a clinical perspective, a Phase I safety and pharmacokinetic (PK) trial of intravenously administered BB3 has been completed successfully in healthy volunteers and BB3 was found to be well tolerated. In addition, a clinical study of intravenously administered BB3 for safety and PK in renal dialysis patients has been completed. While intravenous BB3 is being developed for acute indications, we are also developing oral BB3 for chronic indications. In this fast-track SBIR grant application, we propose to conduct a Phase 1 clinical study evaluating safety and PK of BB3 administered orally in healthy volunteers.
PUBLIC HEALTH RELEVANCE: A small-molecule, hepatically protective and anti-fibrotic agent has significant clinical potential against both liver fibrosis.
描述(申请人提供):肝纤维化是一种影响全球数千万人的疾病,是由于过量饮酒、病毒感染(乙肝和丙型肝炎)、铁超载或肝外梗阻造成的慢性损伤导致的肝脏疤痕反应,可发展为肝硬化、肝功能衰竭和死亡。事实上,由于丙型肝炎流行和与非酒精性脂肪性肝炎相关的肝病发病率上升,预计未来十年死于肝纤维化/肝硬变并发症的人数将增加两倍。目前可用的治疗方法,包括抗病毒药物,在治疗潜在的纤维化方面基本上无效,在大多数情况下,肝移植是唯一有效的治疗方法。肝生长因子(HGF),也被称为散射因子(SF),已被证明在减轻肝纤维化方面有效。然而,HGF作为基因或蛋白质治疗的可行性受到与腺病毒蛋白引起的免疫和炎症反应有关的问题的限制,蛋白质在溶液中的固有不稳定性,其有限的组织半衰期,以及与这种治疗相关的高昂成本。在美国国立卫生研究院(NIH)小企业创新研究(SBIR)和快速介入开发(RAID)计划的支持下,我们发现并开发了一种新型的小分子HGF模拟物BB3。到目前为止,BB3在每一项测试中都复制了HGF的生物活性。特别是,BB3具有细胞保护、抗纤维化和再生活性,并显示出减少肝纤维化的效果。我们计划的总体目标是将BB3作为一种一流的抗肝纤维化药物推向临床。从临床角度来看,静脉注射BB3的I期安全性和药代动力学(PK)试验已经在健康志愿者中成功完成,BB3被发现耐受性良好。此外,静脉注射BB3对肾透析患者的安全性和PK的临床研究已经完成。在开发静脉注射BB3用于急性适应症的同时,我们也正在开发用于慢性适应症的口服BB3。在这项快速通道SBIR赠款申请中,我们建议进行一项第一阶段临床研究,评估健康志愿者口服BB3的安全性和PK。
公共卫生相关性:一种小分子、保护肝脏和抗纤维化的药物具有显著的临床潜力,可对抗这两种肝纤维化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
WEIZHONG CAI其他文献
WEIZHONG CAI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('WEIZHONG CAI', 18)}}的其他基金
Phase I Clinical Study Using an Antifibrotic Drug
使用抗纤维化药物的 I 期临床研究
- 批准号:
8136803 - 财政年份:2011
- 资助金额:
$ 31.13万 - 项目类别:
Unique Clinical Study on DGF Using Paired Kidneys
使用配对肾脏进行 DGF 的独特临床研究
- 批准号:
8062881 - 财政年份:2009
- 资助金额:
$ 31.13万 - 项目类别:
Unique Clinical Study on DGF Using Paired Kidneys
使用配对肾脏进行 DGF 的独特临床研究
- 批准号:
8244441 - 财政年份:2009
- 资助金额:
$ 31.13万 - 项目类别:
Phase I Study of BB3 in Dialysis Patients
BB3 在透析患者中的 I 期研究
- 批准号:
7611557 - 财政年份:2009
- 资助金额:
$ 31.13万 - 项目类别:
TGFb1 Receptor Inhibitors for Liver Fibrosis
TGFb1 受体抑制剂治疗肝纤维化
- 批准号:
7399773 - 财政年份:2008
- 资助金额:
$ 31.13万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 31.13万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 31.13万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 31.13万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 31.13万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 31.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 31.13万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 31.13万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 31.13万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 31.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 31.13万 - 项目类别:
Studentship